171 related articles for article (PubMed ID: 25109965)
1. A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy.
Claus J; Patel G; Ng T; Parker PJ
Biochem Soc Trans; 2014 Aug; 42(4):831-6. PubMed ID: 25109965
[TBL] [Abstract][Full Text] [Related]
2. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
[TBL] [Abstract][Full Text] [Related]
3. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
Choi BK; Fan X; Deng H; Zhang N; An Z
Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
[TBL] [Abstract][Full Text] [Related]
4. Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.
Osada T; Hartman ZC; Wei J; Lei G; Hobeika AC; Gwin WR; Diniz MA; Spector N; Clay TM; Chen W; Morse MA; Lyerly HK
Breast Cancer Res; 2018 Aug; 20(1):90. PubMed ID: 30092835
[TBL] [Abstract][Full Text] [Related]
5. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
[TBL] [Abstract][Full Text] [Related]
6. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models.
Wu Y; Zhang Y; Wang M; Li Q; Qu Z; Shi V; Kraft P; Kim S; Gao Y; Pak J; Youngster S; Horak ID; Greenberger LM
Mol Cancer Ther; 2013 Apr; 12(4):427-37. PubMed ID: 23395887
[TBL] [Abstract][Full Text] [Related]
8. Altered binding avidities and improved growth inhibitory effects of novel anti-HER3 mAb against human cancers in the presence of HER1-or HER2-targeted drugs.
Okita K; Imai K; Kato K; Sugiura R; Endo Y; Masuko K; Tomioka Y; Masuko T
Biochem Biophys Res Commun; 2021 Oct; 576():59-65. PubMed ID: 34482024
[TBL] [Abstract][Full Text] [Related]
9. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
10. Targeting the HER3 pseudokinase domain with small molecule inhibitors.
Colomba A; Claus J; Gao F; George R; Fornili A; Cameron AJM
Methods Enzymol; 2022; 667():455-505. PubMed ID: 35525551
[TBL] [Abstract][Full Text] [Related]
11. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
Rexer BN; Ghosh R; Narasanna A; Estrada MV; Chakrabarty A; Song Y; Engelman JA; Arteaga CL
Clin Cancer Res; 2013 Oct; 19(19):5390-401. PubMed ID: 23948973
[TBL] [Abstract][Full Text] [Related]
12. The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways.
Kovacevic Z; Menezes SV; Sahni S; Kalinowski DS; Bae DH; Lane DJ; Richardson DR
J Biol Chem; 2016 Jan; 291(3):1029-52. PubMed ID: 26534963
[TBL] [Abstract][Full Text] [Related]
13. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.
Mu Z; Klinowska T; Dong X; Foster E; Womack C; Fernandez SV; Cristofanilli M
J Exp Clin Cancer Res; 2014 May; 33(1):47. PubMed ID: 24886365
[TBL] [Abstract][Full Text] [Related]
14. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.
Garner AP; Bialucha CU; Sprague ER; Garrett JT; Sheng Q; Li S; Sineshchekova O; Saxena P; Sutton CR; Chen D; Chen Y; Wang H; Liang J; Das R; Mosher R; Gu J; Huang A; Haubst N; Zehetmeier C; Haberl M; Elis W; Kunz C; Heidt AB; Herlihy K; Murtie J; Schuller A; Arteaga CL; Sellers WR; Ettenberg SA
Cancer Res; 2013 Oct; 73(19):6024-35. PubMed ID: 23928993
[TBL] [Abstract][Full Text] [Related]
15. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.
Wheeler DL; Huang S; Kruser TJ; Nechrebecki MM; Armstrong EA; Benavente S; Gondi V; Hsu KT; Harari PM
Oncogene; 2008 Jun; 27(28):3944-56. PubMed ID: 18297114
[TBL] [Abstract][Full Text] [Related]
17. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
[TBL] [Abstract][Full Text] [Related]
18. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
19. Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer.
Mancini M; Gaborit N; Lindzen M; Salame TM; Dall'Ora M; Sevilla-Sharon M; Abdul-Hai A; Downward J; Yarden Y
Sci Signal; 2015 Jun; 8(379):ra53. PubMed ID: 26038598
[TBL] [Abstract][Full Text] [Related]
20. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.
Sergina NV; Rausch M; Wang D; Blair J; Hann B; Shokat KM; Moasser MM
Nature; 2007 Jan; 445(7126):437-41. PubMed ID: 17206155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
